The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Atypical sphingolipids' lack of C1-OH (hydroxyl group) of sphinganine its the cause they accumulate in the cytoplasm and cannot be degraded. These headless sphingolipids are not able to be phosphorylated and they can neither converted into complex lipids as sphingomyelins and glycosphingolipids (galactosylceramides, gangliosides, cerebrosides ...). Instead, they have toxic effects to the cell. Despite previous opinions that 1-deoxySLs are dead-end metabolites, new researches prove the opposite. Its concentrations decrease over time because atypical sphingolipids convert into downstream products, which normally are polyunsaturated and polyhydroxylated. The main reason for this transformation is detoxification. The enzymes involved in this process produce the change within several days, making it a slow conversion. This take places in two stages:
=== Impact === A study in 2015 found that alcohol and tobacco use combined resulted in a significant health burden, costing over a quarter of a billion disability-adjusted life years. Illicit drug use caused tens of millions more disability-adjusted life years. According to The Lancet, 'four industries (tobacco, unhealthy food, fossil fuel, and alcohol) are responsible for at least a third of global deaths per year'. In 2024, the World Health Organization published a report including these figures. Many Native Americans in the United States have been harmed by, or become addicted to, drinking alcohol. Qualitative analysis reveals that the alcohol industry likely misinforms the public about the dangers of alcohol, similar to the tobacco industry. The alcohol industry influences alcohol policy and health messages, including those for schoolchildren.
== Side effects == The most common adverse effects of Lamividine/zidovudine are similar to other NRTI's and includes headache, neutropenia, anemia, nausea, vomiting, myopathy and nail pigmentation. More serious and potentially life-threatening adverse effects reported include lactic acidosis with hepatic steatosis, but this rare adverse event is mostly associated with Zidovudine. HIV-positive patients with chronic hepatitis B virus (HBV) infections are at risk for potential flares of hepatitis that can occur with abrupt discontinuation of Lamividine/zidovudine because Lamivudine is also used in low doses for treatment against active HBV.
23 July – The World Health Organization (WHO) declares the recent monkeypox outbreak a Public Health Emergency of International Concern, as the number of reported cases worldwide exceeds 17,000. In July, scientists reported that the window to be able to contain the outbreak is closing or has closed. On 5 July, a preprint indicates there can be asymptomatic infections. On 27 July, an analysis of studies by a journalist indicates that "about 10-to-15% of cases have been hospitalized, mostly for pain and bacterial infections that can occur as a result of monkeypox lesions". Studies published in August indicated hospitalizations of small cohorts of early patients were 8% and 13%. 25 July Researchers introduce the concept of necrobotics and demonstrate it by repurposing dead spiders as robotic grippers by activating their gripping arms via applying pressurized air. Researchers review the scientific literature on 100% renewable energy, addressing various issues, outlining open research questions, and concluding there to be growing consensus, research and empirical evidence concerning its feasibility worldwide. 26 July – Scientists analyse 2.8 million of the sequenced SARS-CoV-2 genomes and use the results to compile a 'mutations blacklist' of virus weak spots, and a 'whitelist' of mutations that would make it more transmissible. 27 July – Progress towards a pan coronavirus vaccine is announced, following tests on mice. Antibodies targeting the S2 subunit of SARS-CoV-2's spike protein are found to neutralise multiple coronavirus variants.
Sources: en.wikipedia.org
=== Money laundering === Criminal networks often launder their money in Morocco, southern Spain, or Dubai. This illegal money often circulates through the Hawala system, a parallel banking system of Arab origin that is often used by organised crime syndicates. Interpol also mentioned that the Moroccan mafia has a major involvement in the synthetic drug market, particularly in the manufacturing of these drugs, as well as playing an important role in the trafficking of cannabis (hashish) from the Jbala region in Morocco. In Wouter Laumans' book on the Moroccan mafia, he cites that 80% of northern Morocco is built with illegal money that mostly originates from money laundering. Dutch investigator Pieter Tops made an astonishing discovery in September 2018: trafficking networks in the Netherlands easily collect up to €20 billion through the trade of synthetic drugs such as XTC or amphetamines. Tops warned the Belgian authorities that the traffickers have so much money re-invested in legal businesses, which seriously affects the communities and neighbourhoods from where these traffickers originate. As mayor of Antwerp, Bart De Wever asked for reinforcements to investigate the drug trade and the Moroccan mafia in the city, to intercept a maximum number of people who are involved in these drug trafficking businesses.
== Medicinal properties == Calotropis, a genus of plants that includes species such as Calotropis gigantea and Calotropis procera, has been traditionally used for its medicinal properties in various cultures. The following are some of the reported medicinal uses of Calotropis:
=== Directly affiliated public institutions === China Cooperative Times Management Cadre College Technology Promotion Center Vocational Skills Appraisal and Guidance Center Information Center Audiovisual Center Commercial Printing Center Nanjing Institute for Comprehensive Utilization of Wild Plants Jinan Fruit Research Institute Hangzhou Tea Research Institute Zhengzhou Cotton and Hemp Engineering Technology Design and Research Institute Beijing Institute of Commercial Machinery Tianjin Institute of Renewable Resources Kunming Edible Fungi Research Institute Xi'an Institute of Lacquer Coatings
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.